Literature DB >> 24342857

Developmental mechanisms in the prodrome to psychosis.

Elaine F Walker1, Hanan D Trotman1, Sandra M Goulding1, Carrie W Holtzman1, Arthur T Ryan1, Allison McDonald1, Daniel I Shapiro1, Joy L Brasfield1.   

Abstract

Psychotic disorders continue to be among the most disabling and scientifically challenging of all mental illnesses. Accumulating research findings suggest that the etiologic processes underlying the development of these disorders are more complex than had previously been assumed. At the same time, this complexity has revealed a wider range of potential options for preventive intervention, both psychosocial and biological. In part, these opportunities result from our increased understanding of the dynamic and multifaceted nature of the neurodevelopmental mechanisms involved in the disease process, as well as the evidence that many of these entail processes that are malleable. In this article, we review the burgeoning research literature on the prodrome to psychosis, based on studies of individuals who meet clinical high risk criteria. This literature has examined a range of factors, including cognitive, genetic, psychosocial, and neurobiological. We then turn to a discussion of some contemporary models of the etiology of psychosis that emphasize the prodromal period. These models encompass the origins of vulnerability in fetal development, as well as postnatal stress, the immune response, and neuromaturational processes in adolescent brain development that appear to go awry during the prodrome to psychosis. Then, informed by these neurodevelopmental models of etiology, we turn to the application of new research paradigms that will address critical issues in future investigations. It is expected that these studies will play a major role in setting the stage for clinical trials aimed at preventive intervention.

Entities:  

Mesh:

Year:  2013        PMID: 24342857      PMCID: PMC4593698          DOI: 10.1017/S0954579413000783

Source DB:  PubMed          Journal:  Dev Psychopathol        ISSN: 0954-5794


  157 in total

1.  Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide.

Authors:  Matthew G Frank; Zurine D Miguel; Linda R Watkins; Steven F Maier
Journal:  Brain Behav Immun       Date:  2009-07-30       Impact factor: 7.217

2.  Evidence for neuroprotection by the fenamate NSAID, mefenamic acid.

Authors:  Parto S Khansari; Robert F Halliwell
Journal:  Neurochem Int       Date:  2009-06-27       Impact factor: 3.921

3.  Minor physical anomalies, dermatoglyphic asymmetries, and cortisol levels in adolescents with schizotypal personality disorder.

Authors:  D D Weinstein; D Diforio; J Schiffman; E Walker; R Bonsall
Journal:  Am J Psychiatry       Date:  1999-04       Impact factor: 18.112

4.  Increased stress-induced dopamine release in psychosis.

Authors:  Romina Mizrahi; Jean Addington; Pablo M Rusjan; Ivonne Suridjan; Alvina Ng; Isabelle Boileau; Jens C Pruessner; Gary Remington; Sylvain Houle; Alan A Wilson
Journal:  Biol Psychiatry       Date:  2011-11-30       Impact factor: 13.382

5.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

6.  BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions.

Authors:  Idan Shalev; Elad Lerer; Salomon Israel; Florina Uzefovsky; Inga Gritsenko; David Mankuta; Richard P Ebstein; Marsha Kaitz
Journal:  Psychoneuroendocrinology       Date:  2008-11-05       Impact factor: 4.905

7.  Early traumatic experiences in those at clinical high risk for psychosis.

Authors:  Jean Addington; Jacqueline Stowkowy; Kristin S Cadenhead; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Tyrone D Cannon
Journal:  Early Interv Psychiatry       Date:  2013-01-24       Impact factor: 2.732

Review 8.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

9.  Antisaccade task performance in patients at ultra high risk for developing psychosis.

Authors:  Dorien Nieman; Hiske Becker; Reinaud van de Fliert; Niels Plat; Lo Bour; Hans Koelman; Maria Klaassen; Peter Dingemans; Maurice Niessen; Don Linszen
Journal:  Schizophr Res       Date:  2007-07-26       Impact factor: 4.939

Review 10.  Glucocorticoid hyper- and hypofunction: stress effects on cognition and aggression.

Authors:  Jeansok J Kim; József Haller
Journal:  Ann N Y Acad Sci       Date:  2007-05-18       Impact factor: 5.691

View more
  11 in total

1.  BDNF overexpression prevents cognitive deficit elicited by adolescent cannabis exposure and host susceptibility interaction.

Authors:  Hadar Segal-Gavish; Neta Gazit; Yael Barhum; Tali Ben-Zur; Michal Taler; Shay Henry Hornfeld; Irit Gil-Ad; Abraham Weizman; Inna Slutsky; Minae Niwa; Atsushi Kamiya; Akira Sawa; Daniel Offen; Ran Barzilay
Journal:  Hum Mol Genet       Date:  2017-07-01       Impact factor: 6.150

2.  Timing of menarche and abnormal hippocampal connectivity in youth at clinical-high risk for psychosis.

Authors:  Katherine S F Damme; Ivanka Ristanovic; Teresa Vargas; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2020-04-30       Impact factor: 4.905

3.  Early Detection of Psychosis: Recent Updates from Clinical High-Risk Research.

Authors:  Ariel Schvarcz; Carrie E Bearden
Journal:  Curr Behav Neurosci Rep       Date:  2015-01-18

4.  Equity in Mental Health Services for Youth at Clinical High Risk for Psychosis: Considering Marginalized Identities and Stressors.

Authors:  Joseph S DeLuca; Derek M Novacek; Laura H Adery; Shaynna N Herrera; Yulia Landa; Cheryl M Corcoran; Elaine F Walker
Journal:  Evid Based Pract Child Adolesc Ment Health       Date:  2022-03-23

5.  Translating RDoC to Real-World Impact in Developmental Psychopathology: A Neurodevelopmental Framework for Application of Mental Health Risk Calculators.

Authors:  Leigha A MacNeill; Norrina B Allen; Roshaye B Poleon; Teresa Vargas; K Juston Osborne; Katherine S F Damme; Deanna M Barch; Sheila Krogh-Jespersen; Ashley N Nielsen; Elizabeth S Norton; Christopher D Smyser; Cynthia E Rogers; Joan L Luby; Vijay A Mittal; Lauren S Wakschlag
Journal:  Dev Psychopathol       Date:  2021-12-07

6.  Neurodevelopmental Genomic Strategies in the Study of the Psychosis Spectrum.

Authors:  Raquel E Gur
Journal:  Nebr Symp Motiv       Date:  2016

7.  Cognitive behaviour therapy for anxiety in adolescent with early prodromal of psychosis at boarding school.

Authors:  Niken Yuniar Sari; Budi Anna Keliat; Herni Susanti
Journal:  BMC Nurs       Date:  2019-08-16

Review 8.  Epigenetics, stress, and their potential impact on brain network function: a focus on the schizophrenia diatheses.

Authors:  Vaibhav A Diwadkar; Angela Bustamante; Harinder Rai; Monica Uddin
Journal:  Front Psychiatry       Date:  2014-06-23       Impact factor: 4.157

9.  Early-Life Stress Affects Stress-Related Prefrontal Dopamine Activity in Healthy Adults, but Not in Individuals with Psychotic Disorder.

Authors:  Zuzana Kasanova; Dennis Hernaus; Thomas Vaessen; Thérèse van Amelsvoort; Oliver Winz; Alexander Heinzel; Jens Pruessner; Felix M Mottaghy; Dina Collip; Inez Myin-Germeys
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

10.  HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis.

Authors:  I Valli; N A Crossley; F Day; J Stone; S Tognin; V Mondelli; O Howes; L Valmaggia; C Pariante; P McGuire
Journal:  Transl Psychiatry       Date:  2016-05-03       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.